The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
 
David R. Gandara
Honoraria - Amgen; Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Daiichi Sankyo Alliance; Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); Lilly; Novartis; Ocean Genomics (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst); Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Samuel J Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo/UCB Japan; Exact Sciences; Merck; Mersana; Novartis; Sanofi/Aventis; SERVIER
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
 
Miles Cameron Andrews
Honoraria - MSD Australia; MSD Australia; MSD Australia; Pierre Fabre
Consulting or Advisory Role - BMS Australia (Inst)
Research Funding - MSD Australia (Inst)
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; QED Therapeutics; Taiho Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Taiho Pharmaceutical
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo/Lilly; MedImmune; Pfizer; Relay Therapeutics
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Ramez Nassef Eskander
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Clovis Oncology; Daiichi Sankyo/Lilly; Eisai; Merck; Myriad Genetics; Tesaro
Speakers' Bureau - AstraZeneca/MedImmune; Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Jeremy Snider
Employment - Flatiron Health
Stock and Other Ownership Interests - Flatiron Health; Roche
 
Lilia Bouzit
Employment - Flatiron Health; Flatiron Health
Stock and Other Ownership Interests - Roche
 
Cheryl D. Cho-Phan
Employment - Flatiron Health; Gilead Sciences (I)
Leadership - Gilead Sciences (I)
Stock and Other Ownership Interests - Gilead Sciences (I); Roche; Roche (I)
 
Megan Price
Speakers' Bureau - Exelixis; Taiho Oncology
 
Gerald Li
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Julia C. F. Quintanilha
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - United States Patent: "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", Innocenti F., Quintanilha J., Lin D., Owzar K., Wang J. Filed on July 17, 2020, serial number 16/932002; United States Provisional Patent Application: "Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab induced hypertension", Innocenti F., Quintanilha J. Filed on April 1, 2021, serial number 63/169301
Travel, Accommodations, Expenses - Foundation Medicine
 
Richard S.P. Huang
Employment - Roche/Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Patent on IHC; provisional patent on biomarkers and biomarker methodology.
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
David Fabrizio
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - 1. Novel PD-L1 binding polypeptides for imaging 2. Methods and systems for evaluating tumor mutational burden 3. Therapeutic and diagnostic methods for cancer 4. Targeted therapeutics based on engineered proteins for tyrosine kinase receptors, including
 
Geoffrey R. Oxnard
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Ryon Graf
Employment - Epic Sciences; Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine